MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today the receipt of a Phase I grant from the National Center for Advancing Translations Sciences under auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health. The $250,000 grant under the Award Number R43TR002231 is focused on demonstrating the utility of a non-infectious Minute Virus of Mice-Virus Like Particle for predicting viral clearance during biopharmaceutical process development.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract by the Department of National Defence (DND) valued at approximately $8 million to deliver Anthrasil® (Anthrax Immune Globulin Intravenous [human]) to the Canadian government. This contract award follows the recent approval of Anthrasil by Health Canada under the Extraordinary Use New Drug (EUND) Regulations, which provide a regulatory pathway for products for which collecting clinical information for its intended use in humans is logistically or ethically not possible. Anthrasil is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.
Governor Larry Hogan today announced a series of new initiatives to spur job creation and economic growth in Maryland and further establish the state’s leadership in key STEM-related (Science, Technology, Engineering, Mathematics) industries. The governor was joined by Commerce Secretary Mike Gill, Labor Secretary Kelly Schulz, University System of Maryland Chancellor Robert Caret, Wicomico County Executive Bob Culver, and numerous officials from the counties benefiting from the governor’s expanded jobs initiative.
Are you interested in investing in Montgomery County’s future workforce? Sign up to be a career experience host for WorkSource Montgomery’s Summer RISE program at Summer-rise.com!
Play a key role in a successful initiative that provides Real Interesting Summer Experiences to rising Montgomery County Public School’s juniors and seniors. Last summer, the program supported career exploration and industry insights for more than 360 students with the help of over 185 host organizations. Summer RISE 2017 hosts had rewarding experiences, saying their students were professional, creative, engaged and motivated to learn.
Fresh off receiving $125,000 in new funding from a TEDCO initiative to back more Maryland incubators, Annapolis-based FounderTrac named members of its 2018 cohort last week.
Martine Rothblatt has already made a career out of chasing firsts — be it with creating Sirius satellite radio or more recently racing to make her Silver Spring biotech, United Therapeutics Corp., the first to manufacture an unlimited supply of human organs.
Five years after getting started with a $32 million Series A, the crew at Allakos in San Carlos, CA are getting a $100 million mega-round to put their lead drug to the test.
Scientists at George Mason University have developed a nanotechnology that for the first time can measure a sugar molecule in urine that identifies tuberculosis with high sensitivity and specificity, setting the stage for a rapid, highly accurate and far less-invasive urine test of the disease that could potentially prove to be the difference between life and death in many underdeveloped parts of the world.
On the evening of Nov. 7, Steffanie Strathdee sent out a cryptic tweet: “#Phage researchers! I am working with a team to get Burkholderia cepacia phages to treat a 25 y old woman with CF whose infection has failed all #antibiotics. We need lytic non-lysogenic phage URGENTLY to find suitable phage matches. Email if you can help!” The message was retweeted nearly 400 times.
gel-e Inc., a privately held, clinical-stage medical device company, announces the 510(k) clearance of its adhesive bandage by the U.S. Food and Drug Administration (FDA) for prescription (Rx) and over-the-counter (OTC) use.
This new bandage clearance expands the Company’s label to include the management of moderately to heavily exuding chronic wounds and acute wounds. Under medical supervision, this new adhesive bandage may be used for the management of pressure sores, diabetic ulcers, leg ulcers, donor sites and graft sites, surgical wounds, skin abrasions and lacerations, 1st and 2nd degree burns and traumatic wounds. No medical supervision is required for usage in the management of minor cuts, minor scalds and 1st degree burns, and minor abrasions and lacerations. This newly cleared bandage complements gel-e’s existing vascular closure device cleared for the “management of bleeding wounds such as vascular access sites and percutaneous catheters or tubes.”
A new research initiative by the University of Maryland’s Institute for Bioscience and Biotechnology Research (IBBR) and the University of Pittsburgh could finally uncover how T-cells—the “killer cells” that defend the body from microbes—are alerted to hazardous invaders in the body. Funded by a $3.7 million grant from the National Institutes of Health (NIH), the research will be the first to combine X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy for a unique view of the cell’s alert system, which could lead to innovative therapeutics to fight viruses and tumors.
Congrats to our Emmes India colleagues on the opening of their new office in Bengalaru. This move is a result of their successful contributions to public health research in India and around the world. Best wishes on the new place!
The Food and Drug Administration has approved Mumbai-based Lupin’s Tydemy. The product is a generic version of Bayer’s Safyral (drospirenone, ethinyl estradiol, and levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg).
Tech firms leased more office space in D.C. over a recent 12-month period than the prior year, while coworking spaces signed on for fewer square feet.
Those trends come according to the latest DC Development Report, which was released by the Washington D.C. Economic Partnership at the organization’s annual meeting on Tuesday. WDCEP partners with commercial real estate services firm CBRE on the report, and the results come from a “development census” taken in August.
Immunotherapy draws the lion’s share of attention from top VCs, but startups focused on other types of cancer therapies, such as protein targeting, are also starting to gain recognition.
In the world of D.C. funding, it seems like not much has changed. In 2016, our list of the top 8 venture capital deals for D.C. startups fell between $20 million and $100 million. In 2017, that range for the top 15 falls between $20 million and $190 million, with big name investors swaying the top ranks.
Today, the Greater Washington Partnership (the Partnership), a civic alliance of CEOs that together employ more than 175,000 workers in the region, released a new report that outlines why developing, attracting and retaining digital technology workers will be imperative for the Capital Region’s future growth and economic competitiveness.
Efficiency is all about making the optimal use of your resources. For Life Sciences organizations, efficiency is all about their sales forces reaching the right physician at the right time with the right message. Yet, the current tools are woefully inadequate.
If you were overwhelmed by the news in 2017, you aren’t alone. Every day seemed to bring monumental developments in all spheres of current events, from international relations and gender inequality to health care and domestic energy policy. Science was at the forefront often, so we’ve catalogued the two most important developments in each of five topic areas based on our editor’s top picks and our most popular articles. If getting the daily news feels like drinking from a fire hose, this list can help you stay focused on the science developments that matter.
Humans and bacteria have been clashing for as long as both have inhabited the Earth, and for decades now, humans have had the upper hand. Starting with penicillin in 1942, antibiotics have brought previously untreatable maladies like tuberculosis under control and made surgery far safer.
